Fluocortolone: pharmacokinetics and effect on plasma cortisol level
- PMID: 3743619
- DOI: 10.1007/BF00607956
Fluocortolone: pharmacokinetics and effect on plasma cortisol level
Abstract
The pharmacokinetics of fluocortolone and its effect on plasma cortisol levels are described after oral administration of 20, 50 and 100 mg to 9 healthy adults. The concentrations of fluocortolone and cortisol in plasma were measured simultaneously by HPLC with UV detection. Fluocortolone was rapidly absorbed after all doses, giving the maximum plasma level after 1.4-2.1 h. After ingestion of 20, 50 and 100 mg, the peak levels were 199, 419 and 812 ng/ml, respectively. The maximum plasma levels and areas under the plasma level-time curves increased in proportion to the dose. Post-maximum plasma levels declined monoexponentially with a half-life of 1.76 h. Plasma half-life (t1/2 = 1.76 h), volume of distribution (1.03 l/kg) and oral clearance (6.9 ml/min/kg) were independent of the dose. The intensity and duration of adrenal suppression was dose dependent. Maximum suppression was observed 8 hours after fluocortolone. Clearcut suppression of cortisol levels after 24 hours was only seen following 100 mg fluocortolone.
Similar articles
-
Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.Eur J Clin Pharmacol. 1988;35(2):177-81. doi: 10.1007/BF00609249. Eur J Clin Pharmacol. 1988. PMID: 2847930
-
[Pharmacokinetics of fluocortolone in long term therapy of patients with rheumatic and hematologic diseases].Arzneimittelforschung. 1986 Aug;36(8):1268-71. Arzneimittelforschung. 1986. PMID: 3490855 German.
-
[The metabolism of hydrocortisone, prednisolone and fluocortolone (author's transl)].Wien Klin Wochenschr. 1981 Nov 13;93(21):671-3. Wien Klin Wochenschr. 1981. PMID: 7324480 German.
-
Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.Clin Pharmacokinet. 1976;1(4):233-63. doi: 10.2165/00003088-197601040-00001. Clin Pharmacokinet. 1976. PMID: 13958 Review.
-
High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.Clin Pharmacokinet. 1986 Mar-Apr;11(2):87-106. doi: 10.2165/00003088-198611020-00001. Clin Pharmacokinet. 1986. PMID: 3514045 Review.
Cited by
-
Fluocortolone: pharmacokinetics and effect on ACTH and cortisol secretion during daily and alternate-day administration.Eur J Clin Pharmacol. 1988;35(2):177-81. doi: 10.1007/BF00609249. Eur J Clin Pharmacol. 1988. PMID: 2847930
-
Lack of impairment of fluocortolone disposition in oral contraceptive users.Eur J Clin Pharmacol. 1988;35(1):101-3. doi: 10.1007/BF00555517. Eur J Clin Pharmacol. 1988. PMID: 3220090
-
A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.J Pharmacokinet Biopharm. 1999 Apr;27(2):127-47. doi: 10.1023/a:1020670421957. J Pharmacokinet Biopharm. 1999. PMID: 10567952
-
Susceptibility to and severity of SARS-CoV-2 infection according to prescription drug use-an observational study of 46,506 Danish healthcare workers.PLoS One. 2024 Nov 27;19(11):e0311260. doi: 10.1371/journal.pone.0311260. eCollection 2024. PLoS One. 2024. PMID: 39602471 Free PMC article.
-
Pharmacodynamic modeling of cortisol suppression from fluocortolone.Eur J Clin Pharmacol. 1993;45(6):581-3. doi: 10.1007/BF00315319. Eur J Clin Pharmacol. 1993. PMID: 8157047
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources